Paper Details

  1. Home
  2. Paper Details

Long-Term Effectiveness of Rilpivirine-Based Single-Tablet Regimens in a Seven-Year, Two-Center Observational Cohort of People Living with HIV.

Author: BassettiMatteo, BeltraminiSabrina, BrianoFederica, BrunoSerena Rita, Di BiagioAntonio, FerraraSergio, GiacominiMauro, Lo CaputoSergio, MagnascoLaura, MoraSara, PincinoRachele, PolisenoMariacristina, SarteschiGiovanni, SassoElisabetta, TaramassoLucia

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Overview

Rilpivirine (RPV) is a medication used to treat HIV infection. This retrospective study assessed the rate of discontinuation of the RPV single-tablet regimen (STR) and identified factors associated with the risk of discontinuation. The authors found that the discontinuation rate of RPV-STR was 7.7 per 100 person-years. The most common reasons for discontinuation were loss to follow-up, side effects, and ART optimization. Heterosexual and mother-to-child transmission of HIV infection and a history of previous virological failure were associated with a higher risk of discontinuation.
Paper Details　
Original Abstract of the Article :
Data on the long-term durability of rilpivirine (RPV) are still scarce. A two-center retrospective study was performed, including all people living with HIV (PLWH) treated with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)/RPV or tenofovir alafenamide (TAF)/FTC/RPV in the period January 2013...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1089/AID.2021.0161

データ提供：米国国立医学図書館（NLM）

The Long-Term Effectiveness of Rilpivirine-Based Single-Tablet Regimens for HIV Treatment

This research delves into the effectiveness of rilpivirine (RPV)-based single-tablet regimens (STRs) for the long-term management of HIV. The researchers conducted a retrospective study, analyzing data from a two-center cohort of people living with HIV (PLWH) who had been treated with RPV-based STRs for a period of seven years. They investigated the rate of discontinuation of RPV-STRs and identified factors that may be associated with discontinuation. Their findings suggest that RPV-STRs are highly effective and durable, with a relatively low rate of discontinuation, making them a promising treatment option for long-term HIV management.

A Beacon in the Desert: Long-Term HIV Treatment

The study found that the estimated proportions of discontinuation after 48 and 96 weeks were 5.6% and 13.4%, respectively. This indicates that RPV-STRs are a viable option for long-term management of HIV, providing sustained viral suppression and a good quality of life for many patients. It's like a beacon in the desert, offering hope and stability for those living with HIV.

Navigating the Desert of HIV Management

This research highlights the importance of carefully selecting patients for RPV-STRs based on individual factors such as previous virological failure and mode of transmission. It also underscores the need for continued monitoring and adherence to ensure optimal treatment outcomes. It's like a camel navigating a vast desert, carefully selecting the best routes and preparing for any challenges along the way.

Dr.Camel's Conclusion

This study is like a refreshing spring in the desert of HIV management. It shows that RPV-STRs offer a promising path towards sustained viral suppression and improved quality of life for those living with HIV.

Date :
  1. Date Completed 2022-06-09
  2. Date Revised 2022-08-02
Further Info :

Pubmed ID

35172617

DOI: Digital Object Identifier

10.1089/AID.2021.0161

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.